Results 91 to 100 of about 400,612 (318)

NEW ROLES FOR FC RECEPTORS IN NEURODEGENERATION-THE IMPACT ON IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE

, 2014
There are an estimated 18 million Alzheimer’s disease (AD) sufferers worldwide and with no disease modifying treatment currently available, development of new therapies represents an enormous unmet clinical need.
Teeling, Jessica L., James P. Fuller, Jeffrey B. Stavenhagen, Jessica L. Teeling, Stavenhagen, Jeffrey B., Fuller, James P.   +5 more
core   +1 more source

Additional file 1: of Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimerâ s disease

, 2016
Presents the results of the alternative analysis based on consideration of borderline and positive biomarker values together. (DOCX 27 kb)
Alexopoulos, Panagiotis, Werle, Lukas, Roesler, Jennifer, Thierjung, Nathalie, Gleixner, Lena, Yakushev, Igor, Laskaris, Nikolaos, Wagenpfeil, Stefan, Gourzis, Philippos, Kurz, Alexander, Perneczky, Robert   +10 more
openaire   +1 more source

Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem, Angel Liu, Sargis Manukyan, Mustafa Subhi, Elaina Luskin, Bryan Quah, Sreekanth Madhusoodhanan Nair, Arzu C. Has Silemek, Gabriela Zabala, Yujie Cui, Laura Locke, Paula Barreras, Marwa Kaisey, Vinicius Calsavara, Daniel S. Reich, Nancy L. Sicotte, Pascal Sati, Omar Al‐Louzi   +17 more
wiley   +1 more source

Probabilistic prediction of Alzheimer’s disease from multimodal image data with Gaussian processes

, 2015
Alzheimer’s disease, the most common form of dementia, is an extremely serious health problem, and one that will become even more so in the coming decades as the global population ages.
Young, JM
core  

A direct interaction between mitochondrial proteins and amyloid-β peptide and its significance for the development and treatment of Alzheimer’s disease

, 2015
This work was supported by the Ministry of Education, Youth and Sports CZ (no. LD14009, no. SV/FVZ201201, no. SVV260062), COST CM1103, MH CZ - DRO (UHHK, 00179906), The Alzheimer’s Society, The Barcopel Foundation and the MSD Scottish Life Sciences fund ...
Gunn-Moore, Frank J, Musilek, Kamil, Benek, Ondrej, Kuca, Kamil, Aitken, Laura, Hroch, Lukas   +5 more
core   +1 more source

Topological Measurements of DWI Tractography for Alzheimer’s Disease Detection [PDF]

, 2017
Neurodegenerative diseases affect brain morphology and connectivity, making complex networks a suitable tool to investigate and model their effects. Because of its stereotyped pattern Alzheimer’s disease (AD) is a natural benchmark for the study of novel
Alfonso Monaco, Nicola Amoroso, Sabina Tangaro, Alzheimer’s Disease Neuroimaging Initiative   +3 more
core   +1 more source

Additional file 4: of Older patients are still under-represented in clinical trials of Alzheimerâ s disease

, 2016
Main characteristics of trials included in the age analyses (79). (DOCX 30 kb)
Banzi, Rita, Camaioni, Paolo, Tettamanti, Mauro, Bertele’, Vittorio, Lucca, Ugo   +4 more
openaire   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Assessment of outcome in clinical trials in mild Alzheimer 19s disease: urgent time for a rethink? [PDF]

, 2013
Introduction: A major barrier for clinical trials in Alzheimer's disease is the lack of sensitive clinical endpoints for the early stages. Until recently, regulatory agencies have required demonstration of improvement in two disease domains, cognition ...
McGoldrick, S., Duffy, Fiona, McGoldrick, Susan, Reynish, Emma, Kelly, Fiona, Morrison, Y., Wilson, L., Bennett, Crispin, Wilson, J T Lindsay, Bennett, C., Morrison, Yvonne, Duffy, F., Reynish, E.   +12 more
core  

Variation in TMEM106B in chronic traumatic encephalopathy

Acta Neuropathologica Communications, 2018
The genetic basis of chronic traumatic encephalopathy (CTE) is poorly understood. Variation in transmembrane protein 106B (TMEM106B) has been associated with enhanced neuroinflammation during aging and with TDP-43-related neurodegenerative disease, and ...
Jonathan D. Cherry, Jesse Mez, John F. Crary, Yorghos Tripodis, Victor E. Alvarez, Ian Mahar, Bertrand R. Huber, Michael L. Alosco, Raymond Nicks, Bobak Abdolmohammadi, Patrick T. Kiernan, Laney Evers, Sarah Svirsky, Katharine Babcock, Hannah M. Gardner, Gaoyuan Meng, Christopher J. Nowinski, Brett M. Martin, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz, Robert A. Stern, Lindsay A. Farrer, Ann C. McKee, Thor D. Stein   +26 more
doaj   +1 more source